Outlook Therapeutics reports $11.2M cash; going concern doubt persists

Outlook Therapeutics, Inc.

Preliminary cash and cash equivalents of $11.2M as of June 30, 2026 (unaudited).
Net loss of $62.4M in FY2025; revenue of $1.4M from LYTENAVA sales in Germany/UK.
Going concern: cash only sufficient into September 2026; need substantial additional capital.
$19.8M outstanding under Atlas Sciences note due June 2027; 7.5% exit fee on redemptions.
Terminated ATM prospectus supplement with H.C. Wainwright on Aug 10, 2026; agreement remains.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.